Beactica Therapeutics and Oscotec mutually agree to conclude

/PRNewswire/ -- Beactica Therapeutics AB, the Swedish precision oncology company, and Oscotec Inc. (039200: KOSDAQ), the Korean drug development company, today...

Related Keywords

South Korea , Sweden , Seoul , Soult Ukpyolsi , Uppsala , Uppsala Lan , Swedish , Taeyoung Yoon , Oscotec Inc , Drug Administration , Beactica Therapeutics , Orphan Drug Designation , Drug Designation , Beactica Ab ,